Losmapimod (GW856553X)
Losmapimod (GW856553X) Basic information
- Product Name:
- Losmapimod (GW856553X)
- Synonyms:
-
- 6-[5-(Cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
- GW-856553
- GSK-AHAB
- GW 856553X
- LosMapiMod
- LosMapiMod,GW-856553
- Losmapimod (GW856553X)
- 3-Pyridinecarboxamide, 6-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-
- CAS:
- 585543-15-3
- MF:
- C22H26FN3O2
- MW:
- 383.46
- Product Categories:
-
- Inhibitors
- Mol File:
- 585543-15-3.mol
Losmapimod (GW856553X) Chemical Properties
- Boiling point:
- 529.4±50.0 °C(Predicted)
- Density
- 1.20±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- insoluble in EtOH; insoluble in H2O; ≥19.15 mg/mL in DMSO
- form
- solid
- pka
- 7.75±0.46(Predicted)
- color
- White to off-white
Losmapimod (GW856553X) Usage And Synthesis
Description
GW 856553X is a dual inhibitor of p38α and p38β MAPK (Kis = 0.0079 and 0.025 μM, respectively, in cell-free assays). It is selective for p38α and p38β MAPK over p38γ and p38δ MAPK when used at a concentration of 10 μM. GW 856553X inhibits LPS-induced TNF-α production in isolated rat and human peripheral blood mononuclear cells (PBMCs; IC50s = 0.6 and 0.13 μM, respectively). It decreases disease severity in a mouse model of collagen-induced arthritis when administered at doses ranging from 0.8 to 20 mg/kg. GW 856553X (1.2 and 12 mg/kg) improves survival, normalizes blood pressure, and reduces increases in plasma levels of HDL, LDL, and triglycerides in spontaneously hypertensive stroke-prone rats fed a high-salt high-fat diet.
Uses
Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor.
Definition
ChEBI: 6-[5-[(cyclopropylamino)-oxomethyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide is a phenylpyridine.
target
p38α
References
[1]. willette rn, eybye me, olzinski ar, et al. differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. j pharmacol exp ther, 2009, 330(3): 964-970.
[2]. cheriyan j, webb aj, sarov-blat l, et al. inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. circulation., 2011, 123(5): 515-523.
[3]. lomas da, lipson da, miller be, et al. an oral inhibitor of p38 map kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. j clin pharmacol, 2012, 52(3): 416-424.
Losmapimod (GW856553X)Supplier
- Tel
- 15076683720
- klq@cw-bio.com
- Tel
- sales@boylechem.com
- Tel
- 17702719238 17702719238
- sales@sun-shinechem.com
- Tel
- 0411-62910999 13889544652
- meilunui@163.com
- Tel
- 021-58950125
- info@chemexpress.com